Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Blood (2023) 142 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2023-174338

Published: 2023

Journal Articles

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, Engin Gul, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Victor H. Jimenez-Zepeda, Kevin Song, Hira Mian, Michael Sebag, Debra Bergstrom, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Rayan Kaedbey, Martha L Louzada, Richard LeBlanc

Blood (2023) 142 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2023-181138

Published: 2023

Journal Articles

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 4287–4289.

https://doi.org/10.1182/blood-2022-168843

Published: 2022

Journal Articles

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 289–291.

https://doi.org/10.1182/blood-2022-158219

Published: 2022

Journal Articles

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar Jacques Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Yair Levy, Michael H Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P Chu, Cristina J. Gasparetto, Andrew P. Dalovisio, Michael Sebag, Alexander M Lesokhin

Blood (2022) 140 (Supplement 1): 388–390.

https://doi.org/10.1182/blood-2022-166494

Published: 2022

Journal Articles

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Richard Leblanc, Christopher P. Venner, Esther Masih-Khan, Moustafa Kardjadj, Michael P. Chu, Victor H Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Martha L Louzada, Hira S Mian, Darrell J White, Julie Stakiw, Rami Kotb, Anthony Reiman, Muhammad Aslam, Rayan Kaedbey, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7192–7194.

https://doi.org/10.1182/blood-2022-158679

Published: 2022

Journal Articles

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Maria Murphy, Mathilde Fromentin, Julie Campeau, Michael Sebag, Félix Couture, Jean-François Larouche, Christopher Lemieux, Silvy Lachance, Sandra Cohen, Luigina Mollica, Olivier Veilleux, Isabelle Fleury

Blood (2022) 140 (Supplement 1): 13228–13229.

https://doi.org/10.1182/blood-2022-156473

Published: 2022

Journal Articles

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10002–10004.

https://doi.org/10.1182/blood-2022-163661

Published: 2022

Journal Articles

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Blood (2021) 138 (Supplement 1): 895.

https://doi.org/10.1182/blood-2021-150519

Published: 2021

Journal Articles

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Blood (2021) 138 (Supplement 1): 2751.

https://doi.org/10.1182/blood-2021-150998

Published: 2021

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Journal Articles

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Hira S Mian, Richard Leblanc, Martha L Louzada, Esther Masih-Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H Jimenez-Zepeda, Michael Sebag, Darrell J White, Muhammad Aslam, Kevin W Song, Anthony Reiman, Rami Kotb, Engin Gul, Donna E. Reece

Blood (2021) 138 (Supplement 1): 4721.

https://doi.org/10.1182/blood-2021-148191

Published: 2021

Journal Articles

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Blood (2021) 138 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2021-150232

Published: 2021

Journal Articles

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

Danielle C Croucher, Laura M Richards, Zhihua Li, Ellen nong Wei, Xian Fang Huang, Daniel Waller, Marta Chesi, P. Leif Bergsagel, Michael Sebag, Trevor J. Pugh, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2021-151242

Published: 2021

Journal Articles

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Blood (2021) 138 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2021-146324

Published: 2021

Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134189

Published: 2020

Journal Articles

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-140141

Published: 2020

Journal Articles

Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137183

Published: 2020

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

Journal Articles

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, MD BSc, Christopher P. Venner, MD, Martha L Louzada, MDMSc, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Victor Jimenez-Zepeda, MD, Rami Kotb, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Hira S Mian, MD, Darrell J White, MD, Julie Stakiw, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-142800

Published: 2020

NARROW

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only